logo-loader

Creo Medical under the eye of Proactive research analyst Daniel Appiah

Last updated: 03:07 05 Nov 2022 AEDT, First published: 23:07 04 Nov 2022 AEDT

Creo Medical Group PLC (AIM:CREO) is discussed by Proactive research analyst Daniel Appiah who talks Thomas Warner through his latest report.

Two licensing revenue deals this year will see Creo’s technology used in robotics-assisted laparoscopic (keyhole) surgery to enhance the effectiveness of procedures.

Creo's technology allows minimally invasive endoscopic technology and licensing can be a very important revenue stream in future, Appiah adds. #proactiveinvestors #creomedical

Click here to read the report

The Cenkos Securities Virtual Growth & Innovation Forum

Cenkos Growth & Innovation Forum - Tuesday 8th February  Join Cenkos and Proactive at the Growth & Innovation Forum on Tuesday the 8th February 2022 from 9am onwards. Meet management from exciting, innovationg and growing companies from across the globe.  Listen to company...

on 9/2/22
OSZAR »